Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

PubMed  Google Scholar 

Hu C, Zhang Y, Xu J, Chen W, Yu P, Wang Y, et al. Prognostic significance of serum tumor marker normalization in the perioperative period for patients with advanced gastric cancer. Ann Transl Med. 2022;10(3):153.

Article  PubMed  PubMed Central  Google Scholar 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.

Article  PubMed  CAS  Google Scholar 

Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.

Article  PubMed  CAS  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(2):167–92.

Article  CAS  Google Scholar 

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20.

Article  PubMed  CAS  Google Scholar 

Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.

Article  PubMed  CAS  Google Scholar 

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081–92.

Article  PubMed  CAS  Google Scholar 

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(3):312–9.

Article  PubMed  Google Scholar 

Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212–24.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 Trial. J Clin Oncol. 2024;42(17):2012–20.

Article  PubMed  CAS  Google Scholar 

Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim HD, Lee JS, Park YS, Yook JH, Noh SH, Park YK, et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study. Gastric Cancer. 2022;25(6):1039–49.

Article  PubMed  CAS  Google Scholar 

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.

Article  PubMed  CAS  Google Scholar 

Maguire A, Sheahan K. Controversies in the pathological assessment of colorectal cancer. World J Gastroenterol. 2014;20(29):9850–61.

Article  PubMed  PubMed Central  Google Scholar 

Chetty R, Gill P, Govender D, Bateman A, Chang HJ, Driman D, et al. A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation. Virchows Arch. 2012;460(2):151–5.

Article  PubMed  Google Scholar 

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–62.

Article  PubMed  Google Scholar 

Hu C, Chen W, Li F, Zhang Y, Yu P, Yang L, et al. Deep learning radio-clinical signatures for predicting neoadjuvant chemotherapy response and prognosis from pretreatment CT images of locally advanced gastric cancer patients. Int J Surg (London, England). 2023;109(7):1980–92.

Google Scholar 

Wang W, Peng Y, Feng X, Zhao Y, Seeruttun SR, Zhang J, et al. Development and validation of a computed tomography-based radiomics signature to predict response to neoadjuvant chemotherapy for locally advanced gastric cancer. JAMA Netw Open. 2021;4(8):e2121143.

Article  PubMed  PubMed Central  Google Scholar 

In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Database. Ann Surg Oncol. 2017;24(12):3683–91.

Article  PubMed  Google Scholar 

Jiang Y, Liang X, Han Z, Wang W, Xi S, Li T, et al. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. Lancet Digit Health. 2021;3(6):e371–82.

Article  PubMed  CAS  Google Scholar 

Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26(2):246–52.

Article  PubMed  CAS  Google Scholar 

Weng CM, Zhong Q, Sun YQ, Liu ZY, Ma YB, Zhang ZQ, et al. A novel ypN-TRG staging system for gastric cancer patients after neoadjuvant therapy based on the metro-ticket paradigm: a multicenter and large sample retrospective analysis. Gastric Cancer. 2025;28(3):465–77.

Article  PubMed  CAS  Google Scholar 

HajiEsmailPoor Z, Tabnak P, Baradaran B, Pashazadeh F, Aghebati-Maleki L. Diagnostic performance of CT scan-based radiomics for prediction of lymph node metastasis in gastric cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1185663.

Article  PubMed  PubMed Central  Google Scholar 

Xu Q, Sun Z, Li X, Ye C, Zhou C, Zhang L, et al. Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy. Eur Radiol. 2021;31(11):8765–74.

Article  PubMed  PubMed Central  Google Scholar 

Zhong H, Wang T, Hou M, Liu X, Tian Y, Cao S, et al. Deep learning radiomics nomogram based on enhanced CT to predict the response of metastatic lymph nodes to neoadjuvant chemotherapy in locally advanced gastric cancer. Ann Surg Oncol. 2024;31(1):421–32.

Article  PubMed  Google Scholar 

Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120–7.

Article  PubMed  Google Scholar 

Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11(1):6093.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xue K, Ying X, Bu Z, Wu A, Li Z, Tang L, et al. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial. Chin J Cancer Res. 2018;30(5):516–25.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jin C, Jiang Y, Yu H, Wang W, Li B, Chen C, et al. Deep learning analysis of the primary tumour and the prediction of lymph node metastases in gastric cancer. Br J Surg. 2021;108(5):542–9.

Article  PubMed  CAS